Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Robinson

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
The American Journal of Gastroenterology|September 28, 2016
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With AdalimumabMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|September 18, 2010
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomicsWilliam J Sandborn, Jean-Frédéric Colombel, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
Intestinal Research|July 4, 2017
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trialNagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, et al.
Journal of Crohn'S & Colitis|February 13, 2019
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease StudiesRemo Panaccione, Robert Löfberg, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2015
Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 studyShringi Sharma, Doerthe Eckert, Jeffrey S Hyams, et al.
Advances in Therapy|March 9, 2018
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical StudiesEdouard J Louis, Walter Reinisch, David A Schwartz, et al.
Gastroenterology|December 24, 2013
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysisJeffrey S Hyams, Marla Dubinsky, Joel Rosh, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
The American Journal of Gastroenterology|September 28, 2016
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With AdalimumabMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|September 18, 2010
Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomicsWilliam J Sandborn, Jean-Frédéric Colombel, Stefan Schreiber, et al.
Inflammatory Bowel Diseases|April 16, 2013
Serum adalimumab concentration and clinical remission in patients with Crohn's diseaseYi-Lin Chiu, David T Rubin, Severine Vermeire, et al.
Intestinal Research|July 4, 2017
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trialNagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, et al.
Journal of Crohn'S & Colitis|February 13, 2019
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease StudiesRemo Panaccione, Robert Löfberg, Paul Rutgeerts, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2015
Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 studyShringi Sharma, Doerthe Eckert, Jeffrey S Hyams, et al.
Advances in Therapy|March 9, 2018
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical StudiesEdouard J Louis, Walter Reinisch, David A Schwartz, et al.
Gastroenterology|December 24, 2013
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's diseaseMark T Osterman, William J Sandborn, Jean-Frederic Colombel, et al.
Alimentary Pharmacology & Therapeutics|December 4, 2018
The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysisJeffrey S Hyams, Marla Dubinsky, Joel Rosh, et al.
Pageof 5